Good morning :)
Place Order
Add to Watchlist

Lupin Ltd

LUPIN Share Price

1,980.901.34% (+26.10)
High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP

With a market cap of ₹90,470 cr, stock is ranked 118

Stock is 2.09x as volatile as Nifty

LUPIN Stock Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Good

The stock is underpriced and is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

With a market cap of ₹90,470 cr, stock is ranked 118

Stock is 2.09x as volatile as Nifty

LUPIN Performance & Key Metrics

LUPIN Performance & Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
27.576.290.60%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
37.156.590.82%

LUPIN Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 
62%
Analysts have suggested that investors can buy this stock

from 34 analysts

Price Upside

Earnings Growth

Rev. Growth

See Detailed Forecast

LUPIN Company Profile

Lupin Limited is engaged in producing, developing and marketing a range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) across the world.

Investor Presentation

View older View older 

May 15, 2025

PDF
View Older Presentations

LUPIN Similar Stocks (Peers)

Compare with peers Compare with peers 

LUPIN Similar Stocks (Peers)

Compare with peers Compare with peers 
PE Ratio
36.80
36.80
1Y Return
7.60%
7.60%
Buy Reco %
87.88
87.88
PE Ratio
23.18
23.18
1Y Return
2.20%
2.20%
Buy Reco %
73.33
73.33
PE Ratio
59.65
59.65
1Y Return
17.34%
17.34%
Buy Reco %
70.83
70.83
PE Ratio
19.24
19.24
1Y Return
0.89%
0.89%
Buy Reco %
55.17
55.17
PE Ratio
22.26
22.26
1Y Return
11.97%
11.97%
Buy Reco %
44.44
44.44
Compare with Peers

LUPIN Sentiment Analysis

LUPIN Sentiment Analysis

New
Crisp summary & key insights to decode earnings calls instantly

LUPIN Stock Summary · May 2025

The company has demonstrated robust financial performance, achieving USD 2.7 billion in revenue and a significant EBITDA margin of 23.7%, driven by strategic growth in complex generics and biosimilars. With a strong product pipeline and recent launches, particularly in the U.S. market, it is well-positioned to capitalize on emerging opportunities, despite facing challenges from increased competition and regulatory dynamics. Operational efficiencies are being prioritized, with investments in R&D and manufacturing capabilities enhancing its competitive edge. Additionally, the focus on expanding into tier two and three markets, alongside a commitment to sustainability and compliance, underscores a proactive approach to long-term growth and market resilience. Overall, the outlook remains optimistic, with expectations for sustained double-digit growth supported by strategic initiatives and a diversified portfolio.

LUPIN Stock Growth Drivers
LUPIN Stock Growth Drivers
8
  • Strong Financial Performance

    The company has reported significant financial achievements, including USD 2.7 billion in revenue and USD

  • Successful Product Launches

    The company has successfully launched several key products, including Mirabegron, Spiriva®, and Tolvaptan, contributing to

LUPIN Stock Challenges
LUPIN Stock Challenges
3
  • Impact of Regulatory Changes on Pharmaceutical Innovation

    The U.S. healthcare landscape is facing significant challenges due to regulatory changes, particularly the Most

  • Challenges in Financial Performance and Margin Pressure

    The company is experiencing negative impacts on its core EBITDA margin, which currently stands at

LUPIN Forecast

LUPIN Forecasts

Price

Revenue

Earnings

LUPIN

LUPIN

Income

Balance Sheet

Cash Flow

LUPIN Income Statement

LUPIN Income Statement

Industry refers to the sub-sector this company belongs to.
Lower than Industry Revenue Growth
A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 7.45%, vs industry avg of 10.14%

Decreasing Market Share
Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 6.37% to 5.55%

Loading...

Financial YearFY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025TTM
Total Revenue17,482.1415,950.4215,095.7815,992.5615,300.5816,615.9316,792.5720,141.5022,903.7222,928.63
Raw Materialssubtract5,339.315,111.625,150.545,422.055,847.106,679.566,626.037,100.9117,424.5917,449.50
Power & Fuel Costsubtract377.86433.88442.28443.17414.48443.96479.68493.07
Employee Costsubtract2,849.522,864.712,770.172,986.842,825.902,989.303,087.153,494.57
Selling & Administrative Expensessubtract2,377.172,386.872,513.072,541.162,230.632,490.562,755.543,350.98
Operating & Other expensessubtract1,930.383,316.311,567.762,378.811,277.973,583.281,972.691,771.28
Depreciation/Amortizationsubtract912.231,085.87846.05970.22887.411,658.71880.691,196.811,169.261,169.26
Interest & Other Itemssubtract152.53204.35302.49362.98140.64142.77274.30311.61294.87294.87
Taxes & Other Itemssubtract985.68295.55896.871,156.72459.92155.83286.41507.79733.38733.38
EPS56.705.5613.41-5.9526.83-33.659.4642.0571.9572.02
DPS7.505.005.006.006.504.004.008.0012.008.00
Payout ratio0.130.900.370.240.420.190.170.11

LUPIN Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2025FY 2025

Annual Report Pending

Investor Presentation

May 15PDF
Feb 11PDF
Nov 7PDF
FY 2024FY 2024

Annual report

PDF

Investor Presentation

Aug 4PDF
FY 2023FY 2023

Annual report

PDF

Investor Presentation

May 10PDF
Feb 10PDF
Jan 10PDF
+2 more
FY 2022FY 2022

Annual report

PDF

Investor Presentation

May 19PDF
FY 2021FY 2021

Annual report

PDF
FY 2020FY 2020

Annual report

PDF
FY 2019FY 2019

Annual report

PDF
FY 2018FY 2018

Annual report

PDF
FY 2017FY 2017

Annual report

PDF
FY 2016FY 2016

Annual report

PDF
 

LUPIN Stock Peers

LUPIN Past Performance & Peer Comparison

LUPIN Past Performance & Peer Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Lupin Ltd27.576.290.60%
Sun Pharmaceutical Industries Ltd36.805.990.95%
Cipla Ltd23.183.911.06%
Torrent Pharmaceuticals Ltd59.6516.630.95%

LUPIN Stock Price Comparison

Compare LUPIN with any stock or ETF
Compare LUPIN with any stock or ETF
LUPIN
Loading...

LUPIN Holdings

LUPIN Shareholdings

LUPIN Promoter Holdings Trend

LUPIN Promoter Holdings Trend

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

LUPIN Institutional Holdings Trend

LUPIN Institutional Holdings Trend

Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

LUPIN Shareholding Pattern

LUPIN Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding46.92%17.55%7.86%21.46%6.21%

Jun 2024

Sep 2024

Dec 2024

Mar 2025

LUPIN Shareholding History

LUPIN Shareholding History

Dec '23MarJunSepDec '24Mar16.11%18.28%19.32%21.50%22.04%21.46%

Mutual Funds Invested in LUPIN

Mutual Funds Invested in LUPIN

No mutual funds holding trends are available

Top 5 Mutual Funds holding Lupin Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
1.2184%1.10%-0.09%15/325 (0)
0.7290%1.75%-0.14%20/49 (-4)
0.6620%1.52%0.09%12/113 (+2)

Compare 3-month MF holding change on Screener

LUPIN Insider Trades & Bulk Stock Deals

LUPIN Insider Trades & Bulk Stock Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases containing LUPIN stock

smallcases containing LUPIN stock

A smallcase is a basket of stocks/ETFs that represents an idea or theme.Diversify your risk and buy smallcases that have Lupin Ltd

Loading...
Pharma Tracker

Pharma Tracker

Created by Windmill Capital

LUPIN's Wtg.
7.77%
7.77%
CAGR
20.54%

LUPIN Events

LUPIN Events

LUPIN Dividend Trend

Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.60%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹6.04 every year

Dividends

Corp. Actions

Announcements

Legal Orders

LUPIN Dividend Trend

Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.60%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹6.04 every year

LUPIN Upcoming Dividends

LUPIN Upcoming Dividends

No upcoming dividends are available

LUPIN Past Dividends

LUPIN Past Dividends

Cash Dividend

Ex DateEx DateJul 16, 2024

Final
Final | Div/Share: ₹8.00

Dividend/Share

8.00

Ex DateEx Date

Jul 16, 2024

Cash Dividend

Ex DateEx DateJul 14, 2023

Final
Final | Div/Share: ₹4.00

Dividend/Share

4.00

Ex DateEx Date

Jul 14, 2023

Cash Dividend

Ex DateEx DateJul 14, 2022

Final
Final | Div/Share: ₹4.00

Dividend/Share

4.00

Ex DateEx Date

Jul 14, 2022

Cash Dividend

Ex DateEx DateJul 27, 2021

Final
Final | Div/Share: ₹6.50

Dividend/Share

6.50

Ex DateEx Date

Jul 27, 2021

Cash Dividend

Ex DateEx DateAug 3, 2020

Final
Final | Div/Share: ₹6.00

Dividend/Share

6.00

Ex DateEx Date

Aug 3, 2020

LUPIN Stock News & Opinions

LUPIN Stock News & Opinions

Corporate
Lupin launches Ipratropium Bromide Nasal Solution in US market

Lupin announced the launch of Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06%, in the United States. Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06% are bioequivalent to Atrovent' Nasal Spray, 0.03% and 0.06%, of Boehringer Ingelheim Pharmaceuticals, Inc. Ipratropium Bromide Nasal Solution (Nasal Spray) 0.03% is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis in adults and children aged 6 years and older. Ipratropium Bromide Nasal Solution (Nasal Spray) 0.06% is indicated for the symptomatic relief of rhinorrhea associated with the common cold or seasonal allergic rhinitis for adults and children aged 5 years and older. Ipratropium Bromide Nasal Solution (RLD Atrovent') had estimated annual sales of USD 63 million in the U.S. (IQVIA MAT May 2025). Powered by Capital Market - Live

2 days agoCapital Market - Live
Spotlight
Lupin launches generic version of anticholinergic medication Ipratropium bromide in United States

Ipratropium Bromide Nasal Solution is a bioequivalent to Atrovent Nasal Sprayof Boehringer Ingelheim Pharmaceuticals, Inc. The solution is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis in adults and children aged 6 years and older. According to IQVIA MAT May 2025, Ipratropium Bromide Nasal Solution (RLD Atrovent) had estimated annual sales of $63 million in the U.S. Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The company's consolidated net profit surged 114.9% to Rs 772.52 crore on a 13.6% jump in net sales to Rs 5,562.20 crore in Q4 FY25 over Q4 FY24. The scrip added 1.36% to end at Rs 1982.20 on the BSE today. Powered by Capital Market - Live

2 days agoCapital Market - Live
Spotlight
Lupin gets USFDA nod for Loteprednol Etabonate Ophthalmic Gel

The product is a generic equivalent of Lotemax SM Ophthalmic Gel, 0.38%, marketed by Bausch & Lomb Inc. Lupin is the exclusive first-to-file applicant for this product and is eligible for 180 days of generic drug exclusivity. The product will be manufactured at Lupin's Pithampur facility in India. Loteprednol Etabonate Ophthalmic Gel, 0.38% is a corticosteroid indicated for the treatment of postoperative inflammation and pain following ocular surgery. According to IQVIA MAT data for May 2025, Loteprednol Etabonate Ophthalmic Gel, 0.38% (Reference Listed Drug: Lotemax' SM) had estimated annual sales of $29 million in the U.S. Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The company's consolidated net profit surged 114.9% to Rs 772.52 crore on a 13.6% jump in net sales to Rs 5,562.20 crore in Q4 FY25 over Q4 FY24. The scrip rose 0.85% to Rs 1,978.05 on the BSE.Powered by Capital Market - Live

4 days agoCapital Market - Live
Corporate
Lupin carves-out its LupinLife Consumer Healthcare

Lupin announced the strategic carve-out of its consumer healthcare business, LupinLife Consumer Healthcare  (LCH), into a wholly owned subsidiary, effective 01 July 2025. This initiative aligns with the aspiration to establish a specialized consumer healthcare entity, with an enhanced focus on India's rapidly growing self care market. Since its inception in 2017, LupinLife Consumer Healthcare has emerged as a strong over-the-counter (OTC) healthcare business with a portfolio of scientifically formulated and trusted brands such as Softovac', Beplex Forte', Corcium' and Aptivate'. Anil Kaushal will lead the new independent entity as Chief Executive Officer. This restructuring will enable enhanced focus with targeted investments, leading to increased consumer impact, market expansion, and accelerated growth. Powered by Capital Market - Live

5 days agoCapital Market - Live
Corporate
Lupin receives USFDA approval for Loteprednol Etabonate Ophthalmic Gel

Lupin today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Loteprednol Etabonate Ophthalmic Gel, 0.38%. Loteprednol Etabonate Ophthalmic Gel, 0.38% is bioequivalent to Lotemax' SM Ophthalmic Gel of Bausch & Lomb Inc. Lupin is the exclusive first-to-file for this product and is eligible for 180 days of generic drug exclusivity. This product will be manufactured at Lupin's Pithampur facility in India. Loteprednol Etabonate Ophthalmic Gel, 0.38% is a corticosteroid indicated for the treatment of postoperative inflammation and pain following ocular surgery. Loteprednol Etabonate Ophthalmic Gel, 0.38% (RLD Lotemax' SM) had an estimated annual sale of USD 29 million in the U.S. (IQVIA MAT May 2025). Powered by Capital Market - Live

5 days agoCapital Market - Live
Corporate
Lupin update on transfer of its OTC biz to LUPINLIFE Consumer Healthcare

Lupin has today, 30 June 2025, executed a Business Transfer Agreement (BTA) for transfer of its Over-the-Counter Consumer Healthcare Business (OTC Business) to LUPINLIFE Consumer Healthcare (LCHL), a wholly owned subsidiary of the Company, on a slump sale basis. In terms of the BTA, the said transaction has been completed, and transfer of OTC Business will be effective from 01 July 2025.Powered by Capital Market - Live

6 days agoCapital Market - Live
Spotlight
Lupin launches Prucalopride tablets in U.S. market

Prucalopride Tablets are the bioequivalent of Motegrity' Tablets, developed by Takeda Pharmaceuticals U.S.A., Inc. The medication is indicated for the treatment of chronic idiopathic constipation (CIC) in adult patients. According to IQVIA MAT data for April 2025, the reference drug Motegrity' recorded annual sales of approximately $184 million in the U.S. market. Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The company's consolidated net profit surged 114.9% to Rs 772.52 crore on a 13.6% jump in net sales to Rs 5,562.20 crore in Q4 FY25 over Q4 FY24. The scrip declined 1.11% to Rs 1,913.70 on the BSE. Powered by Capital Market - Live

1 week agoCapital Market - Live
Corporate
Lupin launches Prucalopride Tablets in US market

Lupin'announced the launch of Prucalopride Tablets, 1 mg, and 2 mg, in the United States, following the recent approval of its Abbreviated New Drug Application (ANDA) from the U.S. FDA. Prucalopride Tablets are bioequivalent to Motegrity' Tablets, 1 mg and 2 mg, of Takeda Pharmaceuticals U.S.A. Inc., and indicated for the treatment of chronic idiopathic constipation (CIC) in adults. Prucalopride Tablets, 1 mg, and 2 mg (RLD Motegrity') had estimated annual sales of USD 184 million in the U.S. (IQVIA MAT April 2025). Powered by Capital Market - Live

1 week agoCapital Market - Live
Spotlight
Lupin receives USFDA approval for generic Prucalopride tablets

The tablets are a generic equivalent of Motegrity' Tablets, developed by Takeda Pharmaceuticals U.S.A., Inc., and are indicated for the treatment of chronic idiopathic constipation (CIC) in adults. Lupin stated that the approved product is bioequivalent to Motegrity' and will be manufactured at the company's facility in Goa, India. According to IQVIA MAT data for April 2025, Prucalopride Tablets (Reference Listed Drug: Motegrity') had estimated annual sales of approximately $184 million in the United States. Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The company's consolidated net profit surged 114.9% to Rs 772.52 crore on a 13.6% jump in net sales to Rs 5,562.20 crore in Q4 FY25 over Q4 FY24. The scrip rose 0.07% to Rs 1,932.10 on the BSE. Powered by Capital Market - Live

1 week agoCapital Market - Live
Corporate
Lupin receives USFDA approval for Prucalopride Tablets

Lupin has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Prucalopride Tablets, 1 mg, and 2 mg. Prucalopride Tablets are bioequivalent to Motegrity' Tablets, 1 mg and 2 mg, of Takeda Pharmaceuticals U.S.A. Inc. This product will be manufactured at Lupin's Goa facility in India. Prucalopride Tablets are indicated for the treatment of chronic idiopathic constipation (CIC) in adults. Prucalopride Tablets, 1 mg, and 2 mg (RLD Motegrity') had estimated annual sales of USD 184 million in the U.S. (IQVIA MAT April 2025). Powered by Capital Market - Live

1 week agoCapital Market - Live

Frequently asked questions

Frequently asked questions

  1. What is the share price of Lupin Ltd (LUPIN) today?

    The share price of LUPIN as on 4th July 2025 is ₹1980.90. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. What is the return on Lupin Ltd (LUPIN) share?

    The past returns of Lupin Ltd (LUPIN) share are
    • Past 1 week: 0.87%
    • Past 1 month: -0.11%
    • Past 3 months: 0.50%
    • Past 6 months: -16.07%
    • Past 1 year: 12.60%
    • Past 3 years: 215.28%
    • Past 5 years: 126.25%

  3. What are the peers or stocks similar to Lupin Ltd (LUPIN)?
  4. What is the dividend yield % of Lupin Ltd (LUPIN) share?

    The current dividend yield of Lupin Ltd (LUPIN) is 0.60.

  5. What is the market cap of Lupin Ltd (LUPIN) share?

    Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Lupin Ltd (LUPIN) is ₹90470.90 Cr as of 4th July 2025.

  6. What is the 52 week high and low of Lupin Ltd (LUPIN) share?

    The 52-week high of Lupin Ltd (LUPIN) is ₹2402.90 and the 52-week low is ₹1651.15.

  7. What is the PE and PB ratio of Lupin Ltd (LUPIN) stock?

    The P/E (price-to-earnings) ratio of Lupin Ltd (LUPIN) is 27.57. The P/B (price-to-book) ratio is 6.29.

  8. Which sector does Lupin Ltd (LUPIN) belong to?

    Lupin Ltd (LUPIN) belongs to the Health Care sector & Pharmaceuticals sub-sector.

  9. How to buy Lupin Ltd (LUPIN) shares?

    You can directly buy Lupin Ltd (LUPIN) shares on Tickertape. Simply sign up, connect your demat account and place your order.